U.S. AI in Dermatology Diagnosis Market Size, Share, Opportunities, And Trends By Type (Standalone AI Systems, AI-Powered Mobile Apps), By Technology (Machine Learning, Deep Learning, Computer Vision, Natural Language Processing, Others), By Application (Skin Cancer Diagnosis, Acne And Rosacea Diagnosis, Psoriasis Diagnosis, Eczema Diagnosis, Hair And Nail Disorders Diagnosis, Others), And By End-User (Hospitals And Clinics, Dermatology Clinics And Centers, Research Institutes And Academic Centers, Others) - Forecasts From 2025 To 2030

Description

U.S. AI in Dermatology Diagnosis Market Size:

The U.S. AI in Dermatology Diagnosis Market is expected to grow significantly during the forecast period.

U.S. AI in Dermatology Diagnosis Market Introduction:

Integrating AI into dermatology diagnosis represents a transformative shift in healthcare, particularly in the United States, where technological innovation and a robust healthcare infrastructure converge to address the growing burden of skin diseases. AI, leveraging advanced machine learning (ML) and deep learning (DL) algorithms, is revolutionizing dermatological care by enhancing diagnostic accuracy, optimizing clinical workflows, and improving access to specialized care. This technology is particularly impactful in dermatology due to the visual nature of the specialty, where clinical and dermoscopic images serve as primary diagnostic tools. The US, with its advanced technological ecosystem and high prevalence of skin disorders, is a leading market for AI-driven dermatological solutions.

AI in dermatology diagnosis encompasses a range of applications, from image-based analysis for detecting skin cancers like melanoma to classifying inflammatory conditions such as psoriasis and atopic dermatitis. The technology leverages convolutional neural networks (CNNs), transfer learning, and large language models (LLMs) to analyze clinical images, dermoscopy data, and electronic health records (EHRs). In the US, skin cancer is the most common cancer, with melanoma alone accounting for the majority of skin cancer-related deaths in 2024, equating to roughly 8,000 fatalities annually. The rising incidence of skin disorders, coupled with a shortage of dermatologists—estimated at a ratio of 3.3 dermatologists per 100,000 people in some regions—has created a pressing need for scalable diagnostic solutions. AI addresses this gap by enabling faster, more accurate diagnoses, particularly in underserved areas where access to specialists is limited.

Recent advancements in AI have led to the development of computer-aided diagnosis (CAD) systems, such as FotoFinder, which combine digital dermoscopy with image analysis algorithms to enhance lesion detection and monitoring. Studies have demonstrated that AI systems can achieve diagnostic accuracy comparable to or surpassing that of board-certified dermatologists. For instance, a 2020 study showed that a deep learning CNN achieved sensitivity and specificity ranges between 70% and 80% for onychomycosis diagnosis, outperforming many dermatologists. These systems are increasingly integrated into clinical practice, supported by innovations like 3D imaging and telereflectance confocal microscopy, which improve the precision of pattern detection and diagnostic outcomes.

Recent developments underscore the rapid evolution of AI in dermatology. In April 2024, Stanford researchers demonstrated that deep learning-powered AI algorithms improved skin cancer diagnostic accuracy for physicians and medical students, signaling broader adoption in clinical training. Additionally, advancements in multi-modal AI models, which combine image and text data, are enhancing diagnostic precision and personalization. The emergence of startups focusing on AI-driven dermatology solutions, with numerous active companies globally in 2023, reflects growing commercial interest, though many lack peer-reviewed validation.

U.S. AI in Dermatology Diagnosis Market Drivers:

• Rising Prevalence of Skin Disorders

The increasing incidence of skin conditions, such as melanoma, basal cell carcinoma, psoriasis, and atopic dermatitis, is a primary driver for AI adoption in dermatology. Skin cancer remains the most common cancer in the US, with melanoma being particularly deadly if not detected early. Chronic skin conditions like psoriasis affect millions, contributing to a significant healthcare burden. AI’s ability to analyze high-resolution clinical and dermoscopic images enables early detection, which is critical for improving patient outcomes. For instance, AI systems can identify subtle patterns in skin lesions that may be missed by the human eye, facilitating timely interventions. The growing burden of skin diseases, coupled with an aging population and environmental factors like UV exposure, amplifies the need for scalable, AI-driven diagnostic solutions that can support clinicians in managing high patient volumes efficiently.

• Technological Advancements

Rapid progress in AI, particularly in deep learning and computer vision, has significantly enhanced the capabilities of diagnostic tools in dermatology. CNNs, such as those adapted from Google’s Inception or Microsoft’s ResNet, have been fine-tuned for dermatology-specific tasks through transfer learning, enabling high accuracy in classifying skin lesions. Recent innovations, such as multi-modal AI models that integrate image and text data from electronic health records, have further improved diagnostic precision. For example, AI systems can now combine dermoscopic images with patient history to provide personalized diagnostic insights. Collaborative efforts, such as partnerships between academic institutions and tech companies, are accelerating the development of these tools, making them more accessible for clinical use. These advancements not only improve diagnostic accuracy but also streamline workflows, allowing dermatologists to focus on complex cases.

• Shortage of Dermatologists and Demand for Telemedicine

The US faces a persistent shortage of dermatologists, particularly in rural and underserved areas, where access to specialized care is limited. This gap creates significant delays in diagnosis and treatment, particularly for time-sensitive conditions like melanoma. AI-powered diagnostic tools, integrated with telemedicine platforms, enable primary care providers and non-specialists to perform preliminary assessments with high accuracy. For instance, AI-driven teledermatology systems allow clinicians to upload images for analysis, receiving real-time diagnostic support that bridges the gap between primary and secondary care. These systems are particularly valuable in remote regions, where patients may otherwise face long wait times or travel significant distances to see a dermatologist. The rise of telemedicine, accelerated by the COVID-19 pandemic, has further amplified the demand for AI tools that can support virtual consultations and improve access to care.

U.S. AI in Dermatology Diagnosis Market Restraints:

• Data Quality and Representation Issues

The effectiveness of AI in dermatology diagnosis relies heavily on the quality and diversity of training datasets. A significant challenge is the underrepresentation of skin of color (SOC) in these datasets, which leads to algorithmic bias and reduced diagnostic accuracy for patients with darker skin tones. Many AI models are trained on datasets primarily composed of images from lighter skin types, resulting in lower sensitivity for detecting conditions like melanoma or inflammatory disorders in SOC populations. This issue not only undermines the equity of AI-driven care but also raises concerns about misdiagnosis and disparities in health outcomes. Efforts to address this restraint include calls for more inclusive datasets and standardized protocols for data collection, but progress remains slow, posing a barrier to widespread adoption.

• Ethical and Regulatory Challenges

The ethical concerns and stringent regulatory requirements complicate the integration of AI into clinical dermatology. Ethical issues include algorithmic bias, lack of explainability in AI decision-making, and potential over-reliance on automated systems, which can erode trust among clinicians and patients. From a regulatory perspective, the US Food and Drug Administration (FDA) requires rigorous validation of AI tools to ensure safety and efficacy, which can delay market entry and increase development costs. For example, AI systems must demonstrate robust performance across diverse populations and clinical scenarios to gain approval. Additionally, integrating AI into existing clinical workflows poses challenges, as dermatologists must balance AI recommendations with their clinical judgment. These ethical and regulatory hurdles necessitate ongoing collaboration between developers, clinicians, and regulators to establish frameworks that ensure safe and equitable AI deployment.

U.S. AI in Dermatology Diagnosis Market Segmentation Analysis:

• The AI-Powered mobile apps segment

AI-powered mobile apps represent a dominant segment in the US AI dermatology diagnosis market due to their accessibility, scalability, and direct-to-consumer appeal. These apps leverage smartphone cameras and advanced machine learning algorithms, such as convolutional neural networks (CNNs), to analyze images of skin, hair, or nail conditions, providing users with preliminary assessments. Designed primarily for the lay public, these apps enable patients to monitor skin changes, track moles, or identify potential dermatological issues without immediate clinician intervention. They are particularly valuable in addressing the shortage of dermatologists, especially in rural or underserved areas, by facilitating teledermatology and empowering primary care providers with decision-support tools.

A notable example is the Skin Image Search™ by First Derm, which uses AI to screen for 44 common skin conditions, including skin cancers, by comparing user-uploaded images to a database of medically reviewed cases. In May 2024, this app analyzed over 18,000 skin ailments, identifying potential melanomas, squamous cell carcinomas, and basal cell carcinomas, demonstrating its scalability for population-level screening. Another example is Google’s AI-powered dermatology assist tool, launched as a pilot in 2021, which allows users to upload three images of a skin concern and answer questions about symptoms to receive a list of possible conditions from a knowledge base of 288 conditions. This tool has shown accuracy comparable to board-certified dermatologists, particularly for skin cancer detection, and is designed to account for diverse skin types.

The proliferation of these apps—41 identified in a 2024 study—reflects their popularity, with 34.1% focused on skin cancer detection, 31.7% on general skin and hair condition diagnosis, and others targeting acne, atopic dermatitis, or mole tracking.

• By application, skin cancer diagnosis is rising considerably in the market

Skin cancer diagnosis is the most significant application of AI in dermatology due to the high prevalence of skin cancer in the US and the critical need for early detection to improve outcomes. Skin cancer, including melanoma, basal cell carcinoma (BCC), and squamous cell carcinoma (SCC), is the most common cancer in the US, with early diagnosis significantly reducing mortality rates. AI systems, particularly those using deep learning and image recognition, excel in analyzing dermoscopic and clinical images to identify malignant lesions with high sensitivity and specificity. These systems are critical in supporting dermatologists and non-specialists, especially in primary care settings, where accurate triage can expedite referrals to specialists.

AI applications for skin cancer diagnosis include both standalone systems and mobile apps, with notable advancements in tools like DermaSensor, the first FDA-approved AI-enabled device for skin cancer detection, authorized in 2024 for use by non-dermatologists. This handheld device uses elastic scattering spectroscopy to analyze lesions, achieving a significant percentage of sensitivity and a negative predictive value for identifying benign lesions, enabling primary care providers to make informed referral decisions. Similarly, studies have shown that CNN-based algorithms can outperform dermatologists in specific tasks, such as differentiating melanoma from benign nevi. A Stanford University study trained a CNN on 129,450 clinical images, achieving performance comparable to 21 board-certified dermatologists in classifying keratinocyte carcinomas and melanomas. More recent advancements, such as the MICaps framework, have improved melanoma detection in biopsy images, demonstrating the potential of AI to enhance histopathological analysis.

The focus on skin cancer diagnosis is driven by the growing burden of the disease and the ability of AI to provide objective, reproducible assessments. Datasets like BCN20000, which include histopathologically confirmed images, have improved model reliability, though limitations in skin type diversity remain a challenge. AI’s role in skin cancer diagnosis is particularly impactful in teledermatology, where mobile apps and remote consultation platforms enable early detection in underserved populations, reducing delays in treatment and improving patient outcomes.

U.S. AI in Dermatology Diagnosis Market Key Developments:

• FDA Approval of DermaSensor for Skin Cancer Detection (2024): DermaSensor, the first FDA-cleared AI-enabled device for detecting all major skin cancers (melanoma, basal cell carcinoma, and squamous cell carcinoma), was authorized for use by non-dermatologists in primary care settings. This handheld device uses elastic scattering spectroscopy to analyze skin lesions, providing rapid results to guide referral decisions. Its pivotal trial demonstrated high sensitivity and a strong negative predictive value, enabling primary care providers to identify benign lesions with confidence, thus improving access to early skin cancer detection in underserved areas.
• Stanford’s AI Algorithm Enhances Skin Cancer Diagnostic Accuracy (2024): Researchers at the Stanford Center for Digital Health developed a deep learning-powered AI algorithm that significantly improved the accuracy of skin cancer diagnostics for physicians, nurse practitioners, and medical students. The algorithm, tested in clinical scenarios, demonstrated enhanced performance in identifying malignant lesions, particularly melanoma, by analyzing dermoscopic images.
• Advancements in AI-Powered Mobile Apps for Skin Condition Monitoring (2024): The proliferation of AI-powered mobile apps, such as First Derm’s Skin Image Search™, saw significant updates in 2024, with enhanced capabilities for screening 44 common skin conditions, including skin cancers, acne, and inflammatory disorders. These apps leverage CNNs to analyze user-uploaded images, offering real-time diagnostic insights and facilitating teledermatology. The integration of multimodal AI models, combining image and patient-reported data, improved diagnostic precision, making these apps critical tools for patient self-monitoring and clinician support in remote settings.

Segmentation:

• By Type
  • Standalone AI Systems
  • AI-Powered Mobile Apps                          
• By Technology
  • Machine Learning
  • Deep Learning
  • Computer Vision
  • Natural Language Processing (NLP)
  • Others             
• By Application
  • Skin Cancer Diagnosis
  • Acne And Rosacea Diagnosis
  • Psoriasis Diagnosis
  • Eczema Diagnosis
  • Hair And Nail Disorders Diagnosis
  • Others                       
• By End-User
  • Hospitals And Clinics
  • Dermatology Clinics And Centers
  • Research Institutes And Academic Centers
  • Others          

Table Of Contents

1. EXECUTIVE SUMMARY 

2. MARKET SNAPSHOT

2.1. Market Overview

2.2. Market Definition

2.3. Scope of the Study

2.4. Market Segmentation

3. BUSINESS LANDSCAPE 

3.1. Market Drivers

3.2. Market Restraints

3.3. Market Opportunities 

3.4. Porter’s Five Forces Analysis

3.5. Industry Value Chain Analysis

3.6. Policies and Regulations 

3.7. Strategic Recommendations 

4. US AI IN DERMATOLOGY DIAGNOSIS BY TYPE

4.1. Introduction

4.2. Standalone AI systems

4.3. AI-powered mobile apps

5. US AI IN DERMATOLOGY DIAGNOSIS BY TECHNOLOGY

5.1. Introduction

5.2. Machine Learning

5.3. Deep Learning

5.4. Computer Vision

5.5. Natural Language Processing (NLP)

5.6. Others

6. US AI IN DERMATOLOGY DIAGNOSIS BY APPLICATION

6.1. Introduction

6.2. Skin Cancer Diagnosis

6.3. Acne And Rosacea Diagnosis

6.4. Psoriasis Diagnosis

6.5. Eczema Diagnosis

6.6. Hair And Nail Disorders Diagnosis

6.7. Others 

7. US AI IN DERMATOLOGY DIAGNOSIS BY END-USERS

7.1. Introduction

7.2. Hospitals And Clinics

7.3. Dermatology Clinics And Centers

7.4. Research Institutes And Academic Centers

7.5. Others 

8. COMPETITIVE ENVIRONMENT AND ANALYSIS

8.1. Major Players and Strategy Analysis

8.2. Market Share Analysis

8.3. Mergers, Acquisitions, Agreements, and Collaborations

8.4. Competitive Dashboard

9. COMPANY PROFILES

9.1. DermaSensor, Inc. 

9.2. Skin Analytics Ltd. 

9.3. First Derm 

9.4. DeepX Diagnostics 

9.5. Canfield Scientific, Inc. 

9.6. FotoFinder Systems GmbH 

9.7. VUNO Inc.

Companies Profiled

DermaSensor, Inc. 

Skin Analytics Ltd. 

First Derm 

DeepX Diagnostics 

Canfield Scientific, Inc. 

FotoFinder Systems GmbH 

VUNO Inc.

Related Reports